734 related articles for article (PubMed ID: 12629359)
1. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
2. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.
Heidenreich A; Ohlmann C; Hegele A; Beyer J
Eur Urol; 2005 Jan; 47(1):64-71. PubMed ID: 15582251
[TBL] [Abstract][Full Text] [Related]
3. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
5. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.
Steiner H; Zangerl F; Stöhr B; Granig T; Ho H; Bartsch G; Peschel R
J Urol; 2008 Oct; 180(4):1348-52; discussion 1352-3. PubMed ID: 18707723
[TBL] [Abstract][Full Text] [Related]
6. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
7. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations.
Rassweiler JJ; Seemann O; Henkel TO; Stock C; Frede T; Alken P
J Urol; 1996 Sep; 156(3):1108-13. PubMed ID: 8709319
[TBL] [Abstract][Full Text] [Related]
8. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.
Pedrosa JA; Masterson TA; Rice KR; Bihrle R; Beck SD; Foster RS
J Urol; 2014 Jun; 191(6):1777-82. PubMed ID: 24518787
[TBL] [Abstract][Full Text] [Related]
9. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
10. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
11. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer.
Coogan CL; Hejase MJ; Wahle GR; Foster RS; Rowland RG; Bihrle R; Donohue JP
J Urol; 1996 Nov; 156(5):1656-8. PubMed ID: 8863564
[TBL] [Abstract][Full Text] [Related]
12. Modified and bilateral retroperitoneal lymph node dissection for testicular cancer: peri- and postoperative complications and therapeutic outcome.
Tanaka T; Kitamura H; Kunishima Y; Takahashi S; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Jpn J Clin Oncol; 2006 Jun; 36(6):381-6. PubMed ID: 16762970
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
14. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
15. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
Sweeney P; Millikan R; Donat M; Wood CG; Radtke AS; Pettaway CA; Grossman HB; Dinney CP; Swanson DA; Pisters LL
J Urol; 2003 Jun; 169(6):2113-7. PubMed ID: 12771730
[TBL] [Abstract][Full Text] [Related]
16. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
[TBL] [Abstract][Full Text] [Related]
17. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
18. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
Mosharafa AA; Foster RS; Leibovich BC; Bihrle R; Johnson C; Donohue JP
J Urol; 2003 Jun; 169(6):2126-8. PubMed ID: 12771733
[TBL] [Abstract][Full Text] [Related]
19. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
[TBL] [Abstract][Full Text] [Related]
20. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.
Nash PA; Leibovitch I; Foster RS; Bihrle R; Rowland RG; Donohue JP
J Urol; 1998 Mar; 159(3):707-10. PubMed ID: 9474130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
